MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Endocyte Company Profile (NASDAQ:ECYT)

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $16.25 (208.35% upside)

Current Analysts' Coverage Summary for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetActions
3/3/2015WedbushSet Price TargetBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2014Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2014Citigroup Inc.Reiterated RatingNeutral$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2014Chardan CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2014Cantor FitzgeraldInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2014RBC CapitalLower Price TargetOutperform$20.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2014Piper JaffrayDowngradeOverweight -> Neutral$13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2014Robert W. BairdDowngradeOutperform -> Neutral$36.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2014Roth CapitalBoost Price Target$20.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2014Credit SuisseBoost Price TargetOutperform$24.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2014Leerink SwannLower Price Target$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/4/2013 forward)